Polyphor Pulled Out Of The Mire With EnBiotix Merger
Banks $10m For Inhaled Murepavadin
Just over three years, Polyphor's initial public offering in Switzerland raised CHF165m. Now, with just enough cash to get through the third quarter, it has been saved by a deal with US biotech EnBiotix.
